ACADIA Pharmaceuticals (NASDAQ:ACAD) Research Coverage Started at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a report published on Tuesday, MarketBeat.com reports. The brokerage issued a hold rating and a $22.00 target price on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Price Performance

ACAD opened at $19.77 on Tuesday. The stock has a market capitalization of $3.29 billion, a PE ratio of 25.35 and a beta of 0.37. The firm’s fifty day moving average price is $17.95 and its 200 day moving average price is $16.68. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $26.56.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James Kihara sold 4,073 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now owns 19,863 shares in the company, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,661 shares of company stock worth $414,551. Insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. grew its position in shares of ACADIA Pharmaceuticals by 6.8% in the 4th quarter. Ameritas Investment Partners Inc. now owns 12,519 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 795 shares during the period. Quest Partners LLC grew its position in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,066 shares during the period. Values First Advisors Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Finally, Arete Wealth Advisors LLC grew its position in shares of ACADIA Pharmaceuticals by 15.9% in the 4th quarter. Arete Wealth Advisors LLC now owns 13,700 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 1,875 shares during the period. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.